Immune-Mediated Inflammatory Diseases Market
完整報告名稱與涵蓋範圍
Immune-Mediated Inflammatory Diseases Market Size, Share & Trends Analysis Report By Treatment Type (Traditional Drugs, Biologic Therapies, Novel Therapies), Indication (Asthma, Chronic Obstructive Pulmonary Diseases (COPD), Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis, Others), By Route of Administration, End-Users, Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
報告摘要
The Immune-Mediated Inflammatory Diseases Market is positioned for steady expansion, with a projected CAGR of 7.10% from 2024 to 2031.
Immune-Mediated Inflammatory Diseases covers reshaping how healthcare entities approach this space.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the rising emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immune-Mediated Inflammatory Diseases Market Snapshot
Chapter 4. Global Immune-Mediated Inflammatory Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Immune-Mediated Inflammatory Diseases Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Immune-Mediated Inflammatory Diseases Industry Trends
Chapter 5. Immune-Mediated Inflammatory Diseases Market Segmentation 1: By Indication, Estimates & Trend Analysis
5.1. Market Share by Indication, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Indication:
5.2.1. Asthma, Chronic Obstructive Pulmonary Diseases (COPD)
5.2.2. Inflammatory Bowel Disease (IBD)
5.2.3. Systemic Lupus Erythematosus (SLE)
5.2.4. Rheumatoid Arthritis (RA)
5.2.5. Psoriasis
5.2.6. Others
Chapter 6. Immune-Mediated Inflammatory Diseases Market Segmentation 2: By Treatment Type Area, Estimates & Trend Analysis
6.1. Market Share by Treatment Type Area, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatment Types Area:
6.2.1. Traditional Drugs
6.2.2. Biologic Therapies
6.2.3. Novel Therapies
Chapter 7. Immune-Mediated Inflammatory Diseases Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administrations:
7.2.1. Oral
7.2.2. Parenteral
7.2.3. Others
Chapter 8. Immune-Mediated Inflammatory Diseases Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels:
8.2.1. Hospital Pharmacy
8.2.2. Retail Pharmacy
8.2.3. Others
Chapter 9. Immune-Mediated Inflammatory Diseases Market Segmentation 5: By End User, Estimates & Trend Analysis
9.1. Market Share by End User, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:
9.2.1. Hospitals
9.2.2. Specialty Clinics
9.2.3. Others
Chapter 10. Immune-Mediated Inflammatory Diseases Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Immune-Mediated Inflammatory Diseases Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.2.3. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.2.4. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.2.5. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.2.6. North America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.3. Europe
10.3.1. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.3.3. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.3.4. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.3.5. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.3.6. Europe Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024- 2031
10.4.3. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.4.4. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
10.4.5. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.4.6. Asia Pacific Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts By End User, 2024-2031
10.5. Latin America
10.5.1. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.5.3. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.5.4. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.5.5. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.5.6. Latin America Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
10.6.3. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type Area, 2024-2031
10.6.4. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
10.6.5. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.6.6. Middle East & Africa Immune-Mediated Inflammatory Diseases Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Pfizer Inc
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Abbvie Inc.
11.2.3. Novartis AG
11.2.4. Amgen Inc.
11.2.5. Boehringer Ingelheim International GmbH.
11.2.6. Merck & Co Inc.
11.2.7. Sun Pharmaceutical Industries Ltd.
11.2.8. Teva Pharmaceuticals Industries Ltd.
11.2.9. AstraZeneca
11.2.10. Ampio Pharmaceuticals Inc.
11.2.11. Lilly
11.2.12. Zydus Group
11.2.13. Akorn, Incorporated
11.2.14. Daiichi Sankyo Company, Limited
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們